Regarding CD229, there are already preclinical data that showed that CAR T-cells directed against this protein could be a promising strategy in MM [35] due to its central role in the pathophysiology of MM, its strong and homogeneous expression in myeloma cells and myeloma-propagating precursor cells, and their lack of expression in most normal tissues [25]. Here, LY9 is linked to plasma cell myeloma.